Literature DB >> 24311866

Treating cardiovascular atherosclerotic plaques with Tongmaijiangzhi (TMJZ) capsule.

Hong-Qiang Ren1, Li Zhao2, Zhong Shuang Zhang2, Zhong Wang1, Li Wang1, Jun Cang Duan1, Li Li1, Zhi Hong Zhai1, De Tao Qu1, Hui Huang1.   

Abstract

Atherosclerotic plaques can cause serious syndromes and mortality. Cholesterol accumulation in the plaques can disrupt the arterial flow, with lumen narrowing and stenosis, which contributes to heart attack and sudden cardiac death. The pharmacological treatment to atherosclerotic plaques can be anti-hypertensives, anti-cholesterol, and cleaning of the existed plaques. This work examined the effects of pharmacological Tongmaijiangzhi (TMJZ) capsule on atherosclerotic plaques. The radiological findings of the atherosclerotic plaques of 107 patients receiving TMJZ treatment were analyzed. We found that the TMJZ administration decreases plaque volume and alters the composition in a relatively short period, showing highly promising effects. TMJZ treatment is able to remove the existed atherosclerotic plaques with no side effects observed.

Entities:  

Keywords:  Atherosclerotic plaques; Tongmaijiangzhi; hypertension; stenosis

Mesh:

Substances:

Year:  2013        PMID: 24311866      PMCID: PMC3847381     

Source DB:  PubMed          Journal:  Afr J Tradit Complement Altern Med        ISSN: 2505-0044


  17 in total

Review 1.  Statins in the treatment of acute ischemic stroke.

Authors:  Fabrizio Montecucco; Alessandra Quercioli; Marisol Mirabelli-Badenier; Giorgio Luciano Viviani; Francois Mach
Journal:  Curr Pharm Biotechnol       Date:  2012-01       Impact factor: 2.837

Review 2.  Nanomedicine for the prevention, treatment and imaging of atherosclerosis.

Authors:  Costas Psarros; Regent Lee; Marios Margaritis; Charalambos Antoniades
Journal:  Maturitas       Date:  2012-01-18       Impact factor: 4.342

3.  Correlation between Fc γ R III a and aortic atherosclerotic plaque destabilization in ApoE knockout mice and intervention effects of effective components of chuanxiong rhizome and red peony root.

Authors:  Ye Huang; Hui-jun Yin; Xiao-juan Ma; Jing-shang Wang; Qian Liu; Cai-feng Wu; Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2011-05-25       Impact factor: 1.978

4.  Ginsenoside-Rd, a purified component from panax notoginseng saponins, prevents atherosclerosis in apoE knockout mice.

Authors:  Jie Li; Zhi-Zhong Xie; Yong-Bo Tang; Jia-Guo Zhou; Yong-Yuan Guan
Journal:  Eur J Pharmacol       Date:  2010-11-29       Impact factor: 4.432

5.  Panax notoginseng saponins inhibit Zymosan A induced atherosclerosis by suppressing integrin expression, FAK activation and NF-κB translocation.

Authors:  Zhongming Yuan; Yu Liao; Gang Tian; Hua Li; Yi Jia; Haigang Zhang; Zhenghuai Tan; Xiaohui Li; Wenlong Deng; Kangdong Liu; Yiguan Zhang
Journal:  J Ethnopharmacol       Date:  2011-09-08       Impact factor: 4.360

Review 6.  Pitavastatin: an overview.

Authors:  Yasushi Saito
Journal:  Atheroscler Suppl       Date:  2011-11       Impact factor: 3.235

7.  Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress.

Authors:  Fengrong Jiang; Jinchun Qian; Siyu Chen; Wenbo Zhang; Chang Liu
Journal:  Pharm Biol       Date:  2011-05-10       Impact factor: 3.503

Review 8.  Resveratrol in the prevention and treatment of coronary artery disease.

Authors:  Louis M Chu; Antonio D Lassaletta; Michael P Robich; Frank W Sellke
Journal:  Curr Atheroscler Rep       Date:  2011-12       Impact factor: 5.113

Review 9.  Utility of Lp-PLA2 in lipid-lowering therapy.

Authors:  Sreekanth Racherla; Rohit Arora
Journal:  Am J Ther       Date:  2012-03       Impact factor: 2.688

Review 10.  Emerging therapeutic strategies to enhance HDL function.

Authors:  Santiago Redondo; José Martínez-González; Concha Urraca; Teresa Tejerina
Journal:  Lipids Health Dis       Date:  2011-10-10       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.